Company Announcements - Jia Mei Packaging's stock price increased by 230% from December 17, 2025, to January 6, 2026, leading to a suspension for investigation starting January 7, 2026 [2] - Guosheng Technology's stock rose by 370.2% during the same period, prompting a suspension for investigation effective January 7, 2026 [3] - Fenglong Co., Ltd. indicated that it may apply for a suspension if its stock price continues to rise abnormally [4] - Xinfang Pharmaceutical is facing public prosecution for alleged unit bribery [7] - Shengke Communication's second-largest shareholder plans to reduce its stake by no more than 3% [8] - Chip Origin Technology completed the acquisition of Zhudian Semiconductor [9] - Robotech's subsidiary signed a significant contract for automatic optical switch packaging with a Swiss client [10] - Aerospace Changfeng clarified that it does not engage in brain-computer interface or commercial aerospace businesses [12] - Chengjian Development holds 18.91 million shares of Century Space, making it the fourth-largest shareholder [13] - Sanbo Brain Science is not involved in the research, production, or sales of brain-computer interface products [14] - Weisi Medical's new products in the brain-computer interface field are still in the early market cultivation stage [16] - Mairande's products in the brain-computer interface area are also in the research and market cultivation phase [17] - Guankang Technology plans to acquire 100% of Liaojing Electronics, with stock resuming trading [19] - Yahui Long signed a strategic cooperation framework agreement with Brain Machine Star Chain to expand its presence in the brain-computer interface field [20] - China Satellite Communications warned that its stock price is at a historical high and may experience a significant drop [21] - Beidou Star Communication stated that commercial aerospace is just one application scenario for its products and services [22] Financial Performance - Lier Chemical expects a net profit increase of 113.62% to 132.19% for 2025 [39] - Zhongtai Co., Ltd. anticipates a net profit of 420 million to 480 million yuan for 2025, recovering from a previous loss [38] Financing and Capital Increase - Desai Xiwai is planning to issue H-shares and list on the Hong Kong Stock Exchange [40] - Xingye Yinx is also preparing to issue H-shares for listing on the Hong Kong Stock Exchange [41] Other Significant Events - Baotailong's controlling shareholder was ordered to rectify its failure to fulfill a shareholding increase commitment [42] - *ST Changyao's stock may face termination of listing due to negative net assets and other financial issues [43]

Core Viewpoint - The company, Xinbang Pharmaceutical, has received a prosecution notice from the People's Court of Kaiyang County, Guizhou Province, indicating that it may face criminal charges for unit bribery under Article 393 of the Criminal Law of the People's Republic of China [1] Summary by Relevant Categories Legal Issues - The prosecution notice suggests that the company is accused of violating the law regarding bribery, which could lead to significant legal consequences [1] Financial Impact - The announcement indicates that this major legal issue may have a negative impact on the company's profits [1]

信邦制药1月6日公告，公司于近日收到贵州省开阳县人民检察院《起诉书》，检察院以公司涉嫌单位行 贿罪向法院提起公诉。本次重大事项对公司利润可能会产生一定的不利影响，公司管理层将积极应对可 能发生的危机和风险，以最大程度降低前述不利影响。目前本案件处于法院审理阶段，最终结果以法院 判决为准。 ...

证券代码：002390 证券简称：信邦制药 公告编号：2026-001 2025 年 12 月 11 日，公司披露了《关于公司重大事项的公告》 （公告编号：2025-034），因公司涉嫌单位行贿一案，收到检察机关 《审查起诉阶段委托辩护人/申请法律援助告知书》《犯罪嫌疑人诉 讼权利义务告知书》，告知公司有权委托辩护人，以及诉讼的权利义 务。 近日，公司收到贵州省开阳县人民法院送达的检察院《起诉书》。 根据《起诉书》，检察院认为公司触犯了《中华人民共和国刑法》第 三百九十三条之规定，应当以单位行贿罪追究刑事责任。 二、对公司的影响 本次重大事项对公司利润可能会产生一定的不利影响，公司管理 层将积极应对可能发生的危机和风险，以最大程度降低前述不利影响。 目前本案件处于法院审理阶段，最终结果以法院判决为准。 本案尚未开庭审理，公司已委托辩护律师负责本案诉讼事宜，将 依法配合司法机关工作，积极维护公司合法权益，公司将持续关注上 述事件的后续进展情况，及时履行信息披露义务。 贵州信邦制药股份有限公司 关于公司重大事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗 ...

格隆汇1月6日丨信邦制药(002390.SZ)公布，近日收到贵州省开阳县人民检察院(简称"检察院")《起诉 书》，检察院以公司涉嫌单位行贿罪向法院提起公诉。本次重大事项对公司利润可能会产生一定的不利 影响，公司管理层将积极应对可能发生的危机和风险，以最大程度降低前述不利影响。目前本案件处于 法院审理阶段，最终结果以法院判决为准。本案尚未开庭审理，公司已委托辩护律师负责本案诉讼事 宜，将依法配合司法机关工作，积极维护公司合法权益，公司将持续关注上述事件的后续进展情况，及 时履行信息披露义务。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

信邦制药公告，近日收到贵州省开阳县人民法院送达的检察院《起诉书》。根据《起诉书》，检察院认 为公司触犯了《中华人民共和国刑法》第三百九十三条之规定，应当以单位行贿罪追究刑事责任。本次 重大事项对公司利润可能会产生一定的不利影响。 ...

今年2月法院立案、3月公司首次披露子公司涉案；时隔九个月，信邦制药（002390.SZ）于12月10日公告称，母公司亦因涉嫌单位行贿被移送检察机关审 查起诉。公告同步贴出两份司法文书—《审查起诉阶段委托辩护人/申请法律援助告知书》《犯罪嫌疑人诉讼权利义务告知书》，不过核心内容只有：检 察机关已正式收到监察委员会对信邦制药"单位行贿案"的移送起诉材料，而具体行贿细节仍未披露。 （公告截图：信邦制药官方网站） 这笔交易对安怀略而言是一次完美的资本跃迁。他不仅通过交易获得了信邦制药的大量股份，成为重要股东，更顺势进入上市公司核心层，于2014年被聘 为总经理，并在2016年8月接替张观福出任董事长。这次并购，也被视为安怀略父女日后成为公司实控人的起点。然而，这条捷径布满了荆棘。随着王小 林在反腐风暴中落马，涉案金额高达1.5亿余元，当年交易中的权钱细节被曝光，火苗迅速从子公司科开医药蔓延至上市公司信邦制药本身。2025年12月 10日，信邦制药公告称，公司自身也因涉嫌单位行贿罪被检察机关审查起诉。 这是信邦制药2010年登陆深交所主板以来，第一次以"犯罪嫌疑人"身份出现在官方文书里；也是A股医药板块在2025年迎来 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Core Viewpoint - Xinbang Pharmaceutical has been prosecuted for alleged unit bribery, leading to a significant drop in its stock price, despite efforts to control costs and ongoing challenges in its business performance [2][12][19] Group 1: Legal Issues - On December 10, Xinbang Pharmaceutical announced that it was sent for prosecution by the supervisory committee due to alleged unit bribery, potentially related to its acquisition of Guizhou Kekai Pharmaceutical [2][3] - The case involves former chairman An Huailuo and has been linked to corruption details surrounding the acquisition of Kekai Pharmaceutical [5][15] - The company received legal notifications regarding the prosecution, indicating that the case is currently in the review stage [13][14] Group 2: Stock Market Reaction - Following the announcement, Xinbang Pharmaceutical's stock experienced volatility, initially rising by 10.08% on December 10 before closing at a limit down of 3.74 yuan per share the next day [4][14] - As of December 15, the stock price further declined to 3.3 yuan per share, reflecting the negative impact of the bribery allegations on market perception [19] Group 3: Business Performance Challenges - Despite implementing cost control measures, Xinbang Pharmaceutical's financial performance has continued to decline, with a reported revenue of 60.32 billion yuan in 2024, down 6.63% year-on-year, and a net profit of 1.01 billion yuan, a 64.7% decrease from 2023 [9][19] - In the first half of 2025, revenue fell by 6.62% to 28.45 billion yuan, with significant declines in its core businesses, particularly a 12.1% drop in pharmaceutical distribution [20] - The company has managed to reduce operating costs, with a 5.92% decrease in total operating costs in the first half of 2025, yet net profit still fell by 6.69% to 1.07 billion yuan [10][21] Group 4: Governance Concerns - Xinbang Pharmaceutical's family-style management has raised concerns about its governance capabilities, with significant ownership held by An Huailuo and his daughter An Ji [19] - The company has faced legal disputes regarding board representation, which have further complicated its governance structure [19] - Recent personal controversies involving An Ji have also drawn public attention, adding to the scrutiny of the company's management practices [19]

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]